Results 51 to 60 of about 5,090 (179)

Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction. [PDF]

, 2017
LuIII, a protoparvovirus pathogenic to rodents, replicates in human mitotic cells, making it applicable for use to kill cancer cells. This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM).
Agbandje-McKenna, Mavis, Baker, Timothy S, Chipman, Paul, Cotmore, Susan, D'Abramo, Anthony, Geilen, Lorena, Halder, Sujata, Janssen, Mandy, Kurian, Justin, Mckenna, Robert, Misseldine, Adam, Pittman, Nikéa, Smith, J Kennon, Tattersall, Peter   +13 more
core   +3 more sources

Topical and intralesional therapies for in-transitmelanoma

Melanoma Management, 2019
This report surveys the role of topical and intralesional agents in the management of in-transit melanoma. The extent and progression of in-transit disease is highly variable and many patients can have a protracted period of locoregional control.
Michael A Henderson
doaj   +1 more source

Nanomedicines for the delivery of biologics [PDF]

, 2019
A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs.
Desai, Arpan, Greco, Francesca, Hill, Kathryn, Jones, Arwyn T., Mrsny, Randall J., Pasut, Gianfranco, Perrie, Yvonne, Seib, F. Philipp, Seymour, Leonard W., Uchegbu, Ijeoma F., Wahlich, John   +10 more
core   +6 more sources

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

Journal for ImmunoTherapy of Cancer, 2016
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC
Ann W. Silk, Howard L. Kaufman, Hasan Rehman, Michael P. Kane   +3 more
doaj   +1 more source

The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma [PDF]

, 2015
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human solid tumor and current treatments are ineffective in increasing patients' survival. Thus, the development of new therapeutic approaches for ATC is needed.
Ayyoub, Baeuerle, Bell, Bell, Bell, Benveniste, Bonecchi, Burgert, Chariot, Chieffi, Cobb, Coussens, Curti, Di Cristofano, Dupuy, Fagin, Fernando, Feuerer, Fidler, Fong, Fueyo, Ghosh, Giordano, Guo, Hallden, Hallden, Hanahan, Haugen, Haugen, Hickman, Horwitz, Horwitz, Iwasaki, Kairemo, Karin, Kirn, Kirn, Kracht, Leonardi, Maeda, Mameli, Mantovani, Mantovani, Mantovani, Matsuno, McCart, McKiernan, Melcher, Melillo, Nemunaitis, Okubo, Pinchera, Pollard, Portella, Portella, Portella, Portella, Portella, Portella, Portella, Rabkin, Remick, Ribatti, Rice, Schmittgen, Sheridan, Syed, Tanaka, Udelsman, Vilcek, Weinberg, Wilson   +71 more
core   +2 more sources

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs [PDF]

, 2017
BACKGROUND: Radiogenetic therapy is a novel approach in the treatment of cancer, which employs genetic modification to alter the sensitivity of tumor cells to the effect of applied radiation.
Arafat WO, Arafat WO, Datta R, Deb P, Fiveash JB, Hsu H, Kanzawa T, Kawakami Y, Kufe D, Nandi S, Nenoi M, Nieder C, Pinsker M, Rosenfeld ME, Sonabend AM, Tsai‐Morris CH, Weichselbaum RR   +16 more
core   +4 more sources

Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Immunotherapies for cancers are tested in large numbers of clinical trials. It is difficult for clinicians and researchers to stay current with the evidence, and traditional systematic reviews and clinical guidelines are not suited to ensure a continued overview of all trials and their results.
Kim Boesen, Julian Hirt, Pascal Düblin, Heinz Läubli, Benjamin Kassenda, Lars G. Hemkens, Perrine Janiaud   +6 more
wiley   +1 more source

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

BMC Cancer, 2022
Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates.
Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B. A. G. Haanen   +7 more
doaj   +1 more source